USE OF THE CRF2 RECEPTOR AGONIST AND ITS ACYLATED CONJUGATES

Claims

This document describes CRF2 receptor agonists defined in Chemical Formula (1) or Chemical Formula (2), and their fatty acid conjugates.

1. A peptide of Chemical Formula (1) or a pharmaceutically acceptable salt thereof, wherein Z0 is hydrogen; X0 is absent or deleted; X1 is isoleucyl or phenylalanyl; X2 is valyl or threonyl; X3 is leucyl, valyl or serilyl; X5 is leucyl or valyl; X7 is valyl or isoleucyl; X8 is prolyl or serilyl; X9 is isoleucyl or phenylalanyl; X10 is glycyl, histidyl or tyrosyl; X13 is arginyl, glutaminyl, asparaginyl, glutamyl, aspartyl, alanyl or lysilyl; X15 is leucyl or tryptophanyl; X17 is glutamyl, prolyl or lysyl; X18 is glutaminyl, arginyl, isoleucyl, prolyl or lysyl; X19 is alanyl, glutamyl, prolyl or tryptophanyl; X20 is glutaminyl, asparaginyl, glutamyl, aspartyl, alanyl, arginyl or lysyl; X21 is alanyl or glutaminyl; X22 is arginyl, lysyl, glutaminyl, asparaginyl, aspartyl, alanyl or glutamyl; X23 is alanyl or lysyl; X24 is alanyl, leucyl or glutamyl; X25 is arginyl or lysyl; X26 is glutamyl or glutaminyl; X28 is alanyl or valyl;X29 is threonyl, glutamyl or alanyl; X30 is threonyl, glutamyl or lysyl; X32 is alanyl or arginyl; X33 is arginyl, glutamyl, glutaminyl, asparaginyl, aspartyl, alanyl or lysyl; X34 is isoleucyl or methionyl; X35 is leucyl or phenylalanyl; X36 is alanyl, glutamyl, glutaminyl, asparaginyl, arginyl, lysyl or aspartyl; X37 is arginyl, glutamyl, aspartyl or glutaminyl; and Z39 is OH or NH2. ; 12. A pharmaceutical composition for treating and preventing obesity comprising a therapeutically effective amount of a peptide-fatty acid conjugate of claim 6 and pharmaceutically acceptable excipients.